Blood mononuclear cells in GvHD patients receiving MSC
Research type
Research Study
Full title
Identification of a biomarker predictive of clinical responses to mesenchymal stromal cells in graft-versus-host disease
IRAS ID
180171
Contact name
Francesco Dazzi
Contact email
Sponsor organisation
King's College London
Clinicaltrials.gov Identifier
16/NE/0366,
Duration of Study in the UK
2 years, 3 months, 17 days
Research summary
Bone marrow transplantation is a highly efficacious treatment for leukaemia but is often complicated by graft-versus-host disease (GvHD), which accounts for the main toxicity of the procedure. During the last few years we have developed a hugely successfully national programme to treat severe refractory cases of GvHD with Mesenchymal Stromal Cells (MSC). In order to maximise the effects of this treatment we need to better understand how MSC work. We have recently discovered that MSC injected into GvHD recipients are killed by host immune cells. The dying MSC are fundamental to produce the control of GvHD. For this reason, here we propose to fully characterize the host killer cells in GvHD patients. The data will provide information to select the patients who are more likely to respond to MSC. We will also learn which drugs may interfere with the killer cells and ultimately perfect MSC therapies.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
16/NE/0366
Date of REC Opinion
4 Nov 2016
REC opinion
Favourable Opinion